Publications
Publications
- December 1992 (Revised September 1996)
- HBS Case Collection
ImmuLogic Pharmaceutical Corporation (Abridged)
By: Josh Lerner
Abstract
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are highlighted.
Keywords
Decisions; Initial Public Offering; Entrepreneurship; Going Public; Business Startups; Biotechnology Industry; Pharmaceutical Industry; United States
Citation
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (Abridged)." Harvard Business School Case 293-087, December 1992. (Revised September 1996.)
About The Author
